perpetuity.

It is made available under a CC-BY-NC 4.0 International license .

Title Page:

1

4

- 2 Reverse transcription loop-mediated isothermal amplification combined with
- 3 nanoparticles-based biosensor for diagnosis of COVID-19
- 5 Xiong Zhu ^{1,*}, Xiaoxia Wang ^{1,*}, Limei Han ¹, Ting Chen ¹, Licheng Wang ¹, Huan Li ¹,
- 6 Sha Li¹, Lyfen He¹, Xiaoying Fu¹, Shaojin Chen¹, Mei Xing⁴, Hai Chen¹ and Yi
- 7 Wang ^{2,3,†}
- 8 ¹ Central & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan 572000,
- 9 People's Republic of China.
- 10 ² Department of Respiratory Disease, Beijing Pediatric Research Institute, Beijing
- 11 Children's Hospital, Capital Medical University, National Center for Children's
- Health, Beijing 10045, P. R. China.
- ³ Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Key
- 14 Laboratory of Pediatric Respiratory Infection Disease, National Clinical Research
- 15 Center for Respiratory Diseases, Beijing Children's Hospital, Capital Medical
- University, National Center for Children's Health, Beijing 10045, P. R. China.
- ⁴ Wenchang People's Hospital, Sanya, Hainan 572000, P. R. China.
- 18 Short title: COVID-19 RT-LAMP-NBS assay
- 19 Figure: 6
- **20 Tables**: 0

- 21 Supplementary Materials: 1
- † Correspondence: Yi Wang
- 23 Department of Respiratory Infection Disease, Beijing Pediatric Research Institute,
- 24 Beijing Children's Hospital, National Center for Children's Health, No. 56, Nanlishi
- 25 Road, Xicheng District, Beijing 100045, China.
- 26 E-mail: wildwolf0101@163.com
- 28 *These authors contributed equally to this article

ABSTRCT

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

Given the scale and rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, known as 2019-nCov) infection (COVID-19), the ongoing global SARS-CoV-2 outbreak has become a huge public health issue. Rapid and precise diagnostic methods are thus immediately needed for diagnosing COVID-19, providing timely treatment and facilitating infection control. A one-step reverse transcription loop-mediated isothermal amplification (RT-LAMP) coupled with nanoparticles-based biosensor (NBS) assay (RT-LAMP-NBS) was successfully established for rapidly and accurately diagnosing COVID-19. A simple equipment (such as heating block) was required for maintaining a constant temperature (63°C) for only 40 min. Using two designed LAMP primer sets, Flab (opening reading frame 1a/b) and np (nucleoprotein) genes of SARS-CoV-2 were simultaneously amplified and detected in a 'one-step' and 'single-tube' reaction, and the detection results were easily interpreted by NBS. The sensitivity of SARS-CoV-2 RT-LAMP-NBS was 12 copies (each of detection target) per reaction, and no cross-reactivity was generated from non-SARS-CoV-2 templates. Among clinically diagnosed COVID-19 patients, the analytical sensitivity of SARS-CoV-2 was 100% (33/33) in the oropharynx swab samples, and the assay's specificity was also 100% (96/96) when analyzed the clinical samples collected from non-COVID-19 patients. The total diagnosis test from sample collection to result interpretation only takes approximately 1 h. In sum, the RT-LAMP-NBS is a promising tool for diagnosing the current SARS-CoV-2 infection in first line field, public health and clinical laboratories, especially for resource-challenged regions. **KEYWORDS:** SARS-CoV-2; COVID-19; Rapid diagnosis; Reverse transcription

loop-mediated isothermal amplification; Biosensor.

INTRODUCTION

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

In late December 2019, an unexpected outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, known as 2019-nCov) emerged in Wuhan, Hubei province, China, which had previously not been reported in animals or humans (1). By press time, the novel coronavirus (SARS-CoV-2) has resulted in a huge epidemic in China and other 88 countries/territories, and there have been 98,129 globally confirmed cases of SARS-CoV-2 infection (COVID-19), including 3, 380 deaths (World Health Organization, COVID-19 Situation Report-46) (2). As the current outbreak of COVID-19 continues to evolve, COVID-19 has become a serious global health concern because of the possible fatal progression and rapidly growing numbers of new cases (3). Herein, it is urgently necessary to devise as many specific detection assays as possible to provide early, rapid and reliable diagnosis of COVID-19. Diagnosis of COVID-19 based on clinical symptoms, especially in the early stages of this disease, is extremely difficult as there are no characteristic initial manifestations of COVID-19 (4). Although genome sequencing had high accuracy for diagnose of COVID-19, it was not applicable in rapid diagnosis for clinical large-samples because of its longer sequencing time and high requirements for experimental equipment (5). In the current outbreak of COVID-19, real-time reverse transcription polymerase chain reaction (rRT-PCR) was employed to detect SARS-CoV-2 in public health and clinical laboratories because it a specific and sensitive diagnostic method for detection the novel coronavirus (6). However, rRT-PCR technique strongly relies on complex apparatus, skilled personnel and a stable power supply, the total run time of rRT-PCR test is several hours from the clinical specimens to result reporting. In particular, some regions where outbreaks of COVID-19 emerge usually do not provide sufficient infrastructure for good rRT-PCR diagnostic services, especially for field laboratories and resource-limited settings (7). Hence, there is an urgent requirement for easy-to-use, more rapid and simpler detection techniques for diagnosis of COVID-19.

Loop-mediated isothermal amplification (LAMP), which is the most popular

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

isothermal amplification assay, is able to offer a diagnostic testing option for this scenario (8). The details of LAMP mechanism have been described by previous publications (9). Using the LAMP-based protocols, nucleic acid amplification is conducted under isothermal conditions (e.g., in a heating block) with high efficiency, specificity and speed, eliminating the use of precision thermal cycler for thermal change (9, 10). The LAMP technique is highly specific, because recognition of target sequence by six or eight independent regions is required (11). Thus far, LAMP combined with reverse transcription assay (RT-LAMP) had been developed for the detection of multiple respiratory RNA viruses (e.g., influenza viruses, middle east respiratory syndrome and severe acute respiratory syndrome coronavirus) (12). Regarding these traits of LAMP technique, development of a LAMP-based assay for diagnosis of COVID-19 can overcome the shortcomings posed by rRT-PCR methods, and facilitates rapid diagnosis and surveillance of COVID-19. Up to now, two informal published LAMP assays have been developed for diagnosis of COVID-19, and preliminarily evaluated using clinical or stimulated respiratory samples (13, 14). Unfortunately, only a genetic sequence (Open reading frame 1a/b; F1ab) was amplified and detected in the two systems, an unreliable diagnosis result may be obtained when the two COVID-19 LAMP assays detected a sample with high homology sequence of SARS-CoV-2 (e.g., bat severe acute syndrome-like coronavirus, GenBank KY417152.1). respiratory Traditional monitoring techniques (e.g., agarose gel electrophoresis, SYBR dyes and PH indicator), which were non-specific for COVID-19 LAMP products, were employed for confirming the two COVID-19 LAMP results. In addition, the electrophoresis is a time-consuming and tedious procedure, and the judgment of color change of reaction vessel by unaided eye is potentially subjective. Therefore, there is a continuous command for devising the new LAMP-based assays, which are capable of simultaneously detecting multiple targets of SARS-CoV-2, providing more rapid and objective result, and facilitating simpler diagnosis. Here, a 'one-step' and 'one-tube' RT-LAMP coupled with nanoparticles-based

biosensor (NBS) assay (RT-LAMP-NBS) was developed for diagnosis of COVID-19

114 (Figure 1 and 2). Two target sequences, including Flab and nucleoprotein gene (np),

were simultaneously amplified in an isothermal reaction, and detected in a test step.

We will expound the basic COVID-19 RT-LAMP principle, optimize the reaction

parameters (e.g., amplification temperature), and demonstrate its feasibility.

RESULTS

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

COVID-19 RT-LAMP-NBS design

In the LAMP system (Figure 1), FIP (forward inner primer) initiates the isothermal amplification, and the new strand derived from FIP primer was displaced by the F3 (forward primer) synthesis (Step 1). Then, 2 primers, including BIP (backward inner prime) and B3 (backward primer), annealed to the newly produced strand (Step 2), and displacement enzyme (Bst 2.0) extended in tandem generating a dumb-bell form product (Step 3). Thus, the stem-loop stem product can server as the template for the second stage of the LAMP reaction (exponential amplification). The LB* primer (backward loop primer), which was labeled with biotin at the 5' end, could anneal to a distinct product derived from the exponential LAMP reaction stage (Step 4). The LB* product also severed as the template for next amplification by LF* (forward loop primer), which was modified at the 5' end with hapten (Step 5). As a result, a double-labeled detectable product (LF*/LB* product) was formed, and one end of the LF*/LB* product was labeled with hapten, and the other end with biotin (Step 6, 7). One hapten is assigned to one primer set, which provide the possibility for multiplex LAMP detection. A representative schematic of COVID-19 RT-LAMP-NBS assay were displayed in Figure 2. In the COVID-19 RT-LAMP system, fluorescein (FITC) was assigned to Flab primer set, and digoxigenin (Dig) for np primer set. Hence, Flab-LF* and F1ab-LB* primers were labeled at the 5' end with FITC and biotin, and np-LF* and np-LB* for Dig and biotin, respectively (Figure 2A). With the assistance of AMV (avian myeloblastosis virus reverse transcriptase), the RNA (SARS-CoV-2 template) was converted to cDNA, which acted as the material for subsequent LAMP amplification (Figure 2B). After 40 min at 63°C, Flab-LAMP products were

simultaneously labeled with FITC and biotin, and np-LAMP products for Dig and biotin (Figure 2C).

The principle of NBS visualization of COVID-19 RT-LAMP results

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

As shown in the Figure 3, the result readout of COVID-19 RT-LAMP assay was exhibited using the NBS. The details of NBS was shown Figure 3A (Seen in 'Materials and Method' section). For visualization of COVID-19 RT-LAMP results using NBS, aliquots (0.5 µl) of reaction mixtures were deposited into the sample region (Figure 3B, step 1), and an aliquot (80 µl) running buffer then was deposited on the same region (Figure 3B, step 2). At the detection stage, running buffer moves along NBS through capillary action, and rehydrates the SA-DNPS immobilized in the conjugate pad. The end of F1ab-RT-LAMP products labeled with FITC was captured by the anti-FITC antibody located in TL1 region (Test line 1), and the end of np-RT-LAMP products with Dig was captured by anti-Dig antibody located in TL2 region (Test line 2). The other ends of F1ab- and np-RT-LAMP products, labeled with biotin, bind streptavidin-conjugated color nanoparticles for visualization (Figure 3B, step 3). The excess streptavidin-conjugated color nanoparticles were captured by biotinylated bovine serum albumin immobilized in CL (Control line), which demonstrated the working condition of NBS (Figure 3B, step 3). The interpretation of the COVID-19 RT-LAMP results using NBS was shown in Figure 3C.

Confirmation and detection of F1ab-, np- and COVID-19 RT-LAMP products

The positive vessels of Flab-, np- and COVID-19 RT-MCDA assay were visualized as light green using VDR (Visual detection reagent), while the reaction tubes of negative and blank controls remained colorlessness (**Figure S1**, top row). Using NBS, TL1 and CL were observed on the detection region for positive F1ab-RT-LAMP results, and TL2 and CL for positive np-RT-LAMP results. TL1, TL2 and CL simultaneously appeared on the detection region of NBS for positive COVID-19 RT-LAMP results. Only CL appeared on the analysis area of NBS for negative and blank controls of F1ab-, np- and COVID-19 RT-LAMP results (Figure S1, bottom

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

row). These results indicated that F1ab- and np-LAMP primer sets were available for establish the COVID-19 RT-LAMP NBS assay for rapid and reliable detection of SARS-CoV-2. The parameter of optimal temperature for COVID-19 RT-LAMP technique also was tested, and reaction temperature of 63°C was used for performing the COVID-19 RT-LAMP amplification (Figure S2 and S3). Sensitivity of COVID-19 RT-LAMP-NBS assay The COVID-19 RT-LAMP-NBS was able to detect down 12 copies (each of Flab-plasmid and np-plasmid) (Figure 4). Two target genes were detected and identified in a one-tube reaction (Figure 4A). The COVID-19 RT-LAMP results using NBS were in consistent with turbidity and VDR detection (Figure 4B and 4C), while traditional monitoring techniques (VDR and turbidity) could not facilitate multiplex analysis. Furthermore, the sensitivity of COVID-19 RT-LAMP-NBS assay was in conformity with Flab- and np-RT-LAMP assay (Figure 4, S4 and S5). The optimal duration time of COVID-19 RT-LAMP-NBS assay at the isothermal stage also was determined, and the template level at the detection limit appeared three red lines (TL1, TL2 and CL) when the RT-LAMP reaction was carried out only 30 min at 63°C (Figure S6). For the RNA template detection, a reverse transcription process (10 min) is essential, thus a COVID-19 RT-LAMP reaction time of 40 min was recommended for detection of clinical samples. Therefore, the whole diagnosis process of COVID-19 RT-LAMP-NBS, including sample collection (3 min), rapid RNA extraction (15 min), RT-LAMP reaction (40 min) and result interpretation (<2 min), was finished approximately 1 h (Figure 5). **Specificity of RT-LAMP-NBS assay** The positive COVID-19 RT-LAMP-NBS results were obtained only from positive controls (120 copies each of F1ab-plasmid and np-plasmid) (Table S1). The negative results were observed in all pathogens of non-SARS-CoV-2 (virus, bacteria and fungi), in which only a red band (CL) was observed in the biosensor detection regions,

indicating no cross-reaction with non-SARS-CoV-2 templates (**Table S2**).

Application of the RT-LAMP-NBS assay in clinical samples

Of the total of 129 respiratory samples, which were initially analyzed using rRT-PCR in Sanya People's Hospital in 2020, were enrolled in this report. Particularly, only the RNA templates were used after rRT-PCR performance. Among all the enrolled COVID-19 patients (33), the sensitivity of COVID-19 RT-LAMP-NBS assay 100% (33/33). The specificity was 100% (96/96) for COVID-19 RT-LAMP-NBS assay among non-COVID-19 patients, which were diagnosed as having pneumonia with confirmed pathogen in clinical laboratory of SanYa People's Hospital. These preliminary results revealed that the proposed COVID-19 RT-LAMP-BS assay had a high sensitivity and specificity for diagnosis of SARS-CoV-2 infection.

Discussion

An ongoing epidemic by SARS-CoV-2, starting in last December 2019 in Wuhan, China, is a huge public health concern (15). As of today (9 March 2020), 98 129 total confirmed cases have been documented, with 80 711 cases in China and the remaining cases distributed other 88 countries/regions in every continent (WHO, COVID-19 Situation Report-46) (16). Hence, there has been an immediate requirement for early, rapid and reliable diagnostic tests in the current outbreak. Such detection techniques are required not only in these countries where SARS-CoV-2 infection are spreading but also in countries/regions threated by SARS-CoV-2 infection, even in countries/regions where COVID-19 have not yet been emerged.

Here, we reported a novel LAMP-based test for simple, rapid and reliable diagnosis of COVID-19, name COVID-19 RT-LAMP-NBS. Our assay merged LAMP amplification, reverse transcription, multiplex analysis with nanoparticles-based biosensor, and facilitated the diagnosis of COVID-19 in a one-step, single-tube reaction. Only simple apparatus (e.g., a water bath or a heating block) were need to maintain a constant temperature (63°C) for 40 min. Compared with the developed COVID-19 RT-LAMP assays, the RT-LAMP results in this report were visually and objectively indicated by NBS, which was a simple and easy-to-use platform, avoiding the requirement of complex process (e.g., electrophoresis), special

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

reagents (e.g., PH indicator) and expensive instrument (e.g., real-time turbidity) (13, 14). Total analysis procedure could be complete approximately 1 h, including sample collection (3 min), rapid RNA extraction (15 min), RT-LAMP reaction (40 min) and result interpretation (< 2 min). Considering these traits, COVID-19 RT-LAMP-NBS assay is a rapid, economical and technically simple method, offering a measure of practicality for field and clinical laboratories, especially for resource-challenged settings. Two RT-LAMP primer sets, including Flab-RT-LAMP and np-RT-LAMP primer sets, were specifically designed recognizing eight regions of target genes (Figure 6), guaranteeing the high specificity for SARS-CoV-2 detection. The data of analytical specificity revealed that no false-positive results were produced from non-SARS-CoV-2 templates, and positive results were obtained from positive control and SARS-CoV-2 templates (**Table S1**). Moreover, two targets (F1ab and np genes) could be simultaneously amplified and detected in a 'one-step' RT-LAMP reaction, which further guaranteed the assay's reliability. Thus, our approach could effectively avoid the undesired results yielded from the developed COVID-19 RT-LAMP assays that only amplified and detected a target gene (e.g., F1ab) (13, 14). The data of analytical sensitivity validated that RT-LAMP-NBS assay is sufficiently sensitive for diagnosis of COVID-19. Us this protocol, detection limit of COVID-19 RT-LAMP-NBS was 12 copies each of F1ab-plasmid and np-plasmid, which is in conformity with assay's sensitivity generated from F1ab-RT-LAMP-NBS and N-RT-LAMP-NBS detection (Figure 4, S4 and S5). The COVID-19 RT-LAMP-NBS assay did not improve or decrease the analytical sensitivity when compared with the signlex analysis (F1ab-RT-LAMP and np-RT-LAMP assays). In this report, we did not compare the sensitivity results obtained from COVID-19 RT-LAMP-NBS with rRT-PCR assay, because the quality of commercially available test kits for SARS-CoV-2 detection remains uneven. These commercial rRT-PCR assays used in Sanya People's Hospital produce uninform results when they were applied to analyze the 10-fold diluted plasmid templates. For detection the RNA

templates extracted from respiratory samples, 100% (33/33) of clinical samples

examined by rRT-PCR exhibited completely consistent diagnosis, and analytical

specificity was also 100% (96/96) for COVID-19 RT-LAMP-NBS when analyzing

the RNA templates from non-SARS-CoV-2 infection patients.

Conclusion

269 The one-step single-tube COVID-19 RT-LAMP-NBS assay devised in this report

offers an attractive diagnosis tool for SARS-CoV-2 detection. The nearly

equipment-free platform of COVID-19 RT-LAMP-NBS makes it applicable for

resource-limited laboratories (e.g., field laboratories), and the diagnosis results are

easy to interpret. The high specificity, sensitivity and feasibility of COVID-19

RT-LAMP-NBS assay for detection of SARS-CoV-2, and its low cost and ease of use

make the target assay a valuable diagnosis tool for use in field, clinic, public heath

and primary care laboratories, especially for resource-poor regions.

Materials and Methods

Construction of nanoparticles-based biosensor (NBS)

As shown in **Figure 3A**, NBS contains four components (a sample pad, a conjugate pad, a nitrocellulose membrane and an absorbent pad) (Jie-Yi Biotechnology). Rabbit anti-fluorescein antibody (anti-FITC, 0.2 mg/ml, Abcam. Co., Ltd.), sheep anti-digoxigenin antibody (Anti-Dig, 0.25 mg/mL, Abcam. Co., Ltd.) and biotinylated bovine serum albumin (biotin-BSA, 4 mg/mL, Abcam. Co., Ltd.) were immobilized at detection regions (nitrocellulose membrane, NC) as the test line 1 (TL1), test line 2 (TL2) and control line (CL), respectively, with each line separated by 5 mm. Dye streptavidin coated polymer nanoparticles (SA-DNPs, 129 nm, 10mg mL-1, 100mM borate, pH 8.5 with 0.1% BSA, 0.05% Tween 20 and 10mM EDTA) were immobilized at the conjugated regions. Thus, the NBS devised here can detect three targets (a chromatography control and two target amplicons). The assembled NBS were cut into 4-mm dipsticks, and dryly stored at the room temperature until use.

Primer design

294 Two RT-LAMP primer sets (Flab-RT-LAMP and np-RT-LAMP) were designed according the LAMP mechanism using a specialized software (PrimerExplore V5), 295 which targeted Flab and np gene of SARS-CoV-2 (GenBank MN908947, 296 297 Wuhan-Hu-1) (Figure 6). Then, a Blast analysis of the GenBank nucleotide database was performed for the Flab- and np-LAMP primers to validate sequence specificity. 298 299 The more details of primer design, locations, sequences and modifications were 300 shown in Figure 6 and Table S2. All of the oligomers were synthesized and purified by RuiBo Biotech. Co., Ltd. (Beijing, China) at HPLC purification grade. 301 302 303 **Reverse transcription LAMP reaction (RT-LAMP)** 304 The conventional RT-LAMP (Flab- and np-RT-LAMP) was carried out in a one-step 305 reaction in a 25-µl mixture containing 12.5 µl 2×isothermal reaction buffer [40 mM 306 Tris-HCl (pH 8.8), 40 mM KCl, 16 mM MgSO₄, 20 mM (NH4)₂SO₄, 2 M betaine and 0.2 % Tween-20], 8 U of Bst 2.0 DNA polymerase (New England Biolabs), 5 U of the 307 308 avian myeloblastosis virus reverse transcriptase (Invitrogen), 1.4 mM dATP, 1.4 mM dCTP, 1.4 mM dGTP, 1.4 mM dTTP, 0.4 µM each of F3 and B3, 0.4 µM each of LF, 309 LF*, LB and LB*, 1.6 µM each of FIP and BIP and template (1µl for the standard 310 plasmid). 311 312 The COVID-19 RT-LAMP was also performed in a one-step reaction in a 25-µl mixture containing 12.5 µl 2×isothermal reaction buffer [40 mM Tris-HCl (pH 8.8), 313 40 mM KCl, 16 mM MgSO₄, 20 mM (NH4)₂SO₄, 2 M betaine and 0.2 % Tween-20], 314 8 U of Bst 2.0 DNA polymerase (New England Biolabs), 5 U of the avian 315 myeloblastosis virus reverse transcriptase (Invitrogen), 1.4 mM dATP, 1.4 mM dCTP, 316 317 1.4 mM dGTP, 1.4 mM dTTP, 0.25 µM each of F1ab-F3 and F1ab-B3, 0.25 µM each of Flab-LF, Flab-LF*, Flab-LB and Flab-LB*, 1.0 µM each of Flab-FIP and 318 F1ab-BIP, 0.15 µM each of np-F3 and np-B3, 0.15 µM each of np-LF, np-LF*, np-LB 319 320 and np-LB*, 0.6 µM each of np-FIP and np-BIP and template (1µl for the each 321 standard plasmid, 5µl for samples). The monitoring techniques, including real-time turbidity (LA-320C), visual 322 detection reagents (VDR) and NBS, were employed for confirming the RT-LAMP 323

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

reactions and optimizing the reaction parameters (e.g., reaction temperature and isothermal time). Sensitivity of the RT-LAMP-NBS assay Two standard plasmids (Flab-plasmid and np-plasmid) were commercially constructed by Tianyi-Huiyuan Biotech. Co., Ltd. (Beijing, China), which contain the F1ab and np sequences, respectively. Ten-fold serial dilutions $(1.2 \times 10^4 \text{ to } 1.2 \times 10^{-2})$ copies) of F1ab-plasmid and np-plasmid were used to evaluate assay's sensitivity. The plasmid concentration at detection limit level was employed for testing the duration time required by COVID-19 RT-LAMP-NBS assay. Specificity of the COVID-19 RT-LAMP-NBS assay The specificity of the COVID-19 RT-LAMP-NBS assay was examined by detecting the templates extracted from various pathogens, including viruses, bacteria and fungi (Table S1). Feasibility of COVID-19 RT-LAMP-NBS using clinical samples Respiratory samples were collected from COVID-19 infection patients in SanYa People's Hospital, Hainan, which were defined according to standard diagnosis and treatment criteria of COVID-19 (Trial Version 6). The RNA templates extracted from respiratory samples were used after clinical and laboratory diagnosis, which was conducted using the RT-qPCR kit (Recommended by the China CDC). Collection of these RNA templates and analysis of them were approved by SanYa People's Hospital. 5 μl RNA was used as templates for preforming the COVID-19 RT-LAMP-NBS test.

349 Contributors: Yi Wang and Xiong Zhu conceived and designed this study. Xiong Zhu, Xiaoxia 350 Wang, Licheng Wang, Limei Han, Huan Li, Ting Chen, Shaojin Chen, Mei Xing, Hai Chen and Yi Wang performed the experiments. Xiaoxia Wang, Xiong Zhu and Yi Wang analyze the data. Xiong 351 352 Zhu, Xiaoxia Wang and Yi Wang contributed the reagents and analysis tools. Xiong Zhu, Xiaoxia 353 Wang, Licheng Wang, Limei Han, Huan Li, Ting Chen, Shaojin Chen, Mei Xing and Hai Chen 354 contributed the materials. Yi Wang conducted the software. Xiong Zhu and Xiaoxia Wang drafted the 355 manuscript. Xiong Zhu and Yi Wang revised the manuscript. 356 Funding: This work was supported by grants from the Key Research and Development Program of 357 Hainan Province (ZDYF2019149, ZDYF2017163), and Youth Science Foundation of Natural Science 358 Fund of Hainan Province (818QN326). 359 **Competing interests:** The authors declare that they have no competing interests. 360 Ethical approval: This study was approved by the Ethics Committee of the Sanya People's Hospital 361 (SYPH-2019(41)-2020-03-06). 362 **Data sharing:** No additional data available. 363 Transparency declaration: The lead author and guarantor affirms that the manuscript is an honest, 364 accurate, and transparent account of the study being reported; that no important aspects of the study 365 have been omitted; and that any discrepancies from the study as planned and registered have been 366 explained.

Reference

368

- 369 X.-W. Xu et al., Clinical findings in a group of patients infected with the 2019 novel 370 coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Bmj 371 368, (2020).
- 372 R. Lu et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: 2. 373 implications for virus origins and receptor binding. The Lancet 395, 565 (2020).
- 374 C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak of 3. 375 global health concern. The Lancet 395, 470 (2020).
- 376 4. C. Huang et al., Clinical features of patients infected with 2019 novel coronavirus in 377 Wuhan, China. The Lancet 395, 497 (2020).
- 378 5. F. Wu et al., A new coronavirus associated with human respiratory disease in China. 379 Nature, 1 (2020).
- 380 V. M. Corman et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time 6. 381 RT-PCR. Eurosurveillance 25, (2020).
- 382 7. D. K. Chu et al., Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an 383 outbreak of pneumonia. Clinical chemistry, (2020).
- 384 Y. Wang et al., Loop-mediated isothermal amplification label-based gold nanoparticles 8. 385 lateral flow biosensor for detection of Enterococcus faecalis and Staphylococcus 386 aureus. Frontiers in microbiology 8, 192 (2017).
- 387 9. G. A. Obande, K. K. B. Singh, Current and Future Perspectives on Isothermal Nucleic 388 Acid Amplification Technologies for Diagnosing Infections. Infection and Drug 389 Resistance 13, 455 (2020).
- 390 N. G. Schoepp et al., Rapid pathogen-specific phenotypic antibiotic susceptibility 10. 391 testing using digital LAMP quantification in clinical samples. Science Translational 392 Medicine 9, eaal3693 (2017).
- 393 N. Chotiwan et al., Rapid and specific detection of Asian-and African-lineage Zika 11. 394 viruses. Science translational medicine 9, eaag0538 (2017).
- 395 12. Y. P. Wong, S. Othman, Y. L. Lau, S. Radu, H. Y. Chee, Loop-mediated isothermal 396 amplification (LAMP): a versatile technique for detection of micro-organisms. Journal 397 of applied microbiology 124, 626 (2018).
- 398 L. E. Lamb, S. N. Bartolone, E. Ward, M. B. Chancellor, Rapid Detection of Novel 13. Coronavirus (COVID19) by Reverse Transcription-Loop-Mediated Isothermal 399 400 Amplification. Available at SSRN 3539654, (2020).
- 401 14. L. Yu et al., Rapid colorimetric detection of COVID-19 coronavirus using a reverse 402 tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic 403 plat-form: iLACO. medRxiv, (2020).
- 404 15. D. L. Heymann, N. Shindo, COVID-19: what is next for public health? The Lancet, 405
- 406 16. Q. Liu et al., Assessing the Tendency of 2019-nCoV (COVID-19) Outbreak in China. 407 medRxiv, (2020).

Figure legends

410 411 412

413 414

415

416 417




Figure 1. Outline of LAMP assay

Top row, outline of LAMP with LF* and LB*; Bottom row, schematic depiction of the new forward/backward loop primer (LF*/LB*). LF* was labeled with hapten at the 5' end, and LB* was labeled with biotin at the 5' end.

420

421

422

423




Figure 2. Mechanistic description of the COVID-19 RT-LAMP-NBS assay (A), Preparing the amplification mixtures. (B), RT-LAMP reaction. (C), The detectable COVID-19 RT-LAMP products were formed. F1ab-RT-LAMP products were simultaneously labeled with FITC and biotin, and np-RT-LAMP labeled with Dig and biotin.

perpetuity.

It is made available under a CC-BY-NC 4.0 International license .




Figure 3. The principle of NBS for visualization of COVID-19 RT-LAMP products

(A), The details of NBS. (B), The principle of NBS for COVID-19 RT-LAMP products. (C), Interpretation of the COVID-19 RT-LAMP results. I, a positive result for F1ab and np (TL1, TL2 and CL appear on the NBS); II, a positive result for N (TL2 and CL appear on the detection region); III, a positive result for F1ab (TL1 and CL appear on the detection region); IV, negative (only the control line appears on the NBS).

439 440

441

442

443

444

445

446




Figure 4. Sensitivity of COVID-19 RT-LAMP-NBS assay

A, NBS applied for reporting the results; B, Real-time turbidity applied for reporting the results; C, VDR applied for reporting the results. NBS (A)/Signals (B)/Tubes (C) 1-8 represented the plasmid levels (each of F1ab-plasmid and np-plasmid) of 1.2x10⁴, 1.2×10^{3} , 1.2×10^{2} , 1.2×10^{1} , 1.2×10^{0} , 1.2×10^{-1} , 1.2×10^{-2} copies per reaction and blank control (DW). The plasmid levels of 1.2×10^4 to 1.2×10^1 copies per reaction produced the positive reactions.

449

450

451

452

453 454

455 456

457 458

459

460

461

462

463 464

465

466



Figure 5. The workflow of COVID-19 RT-LAMP-BS assay

Four steps, including sample collection (3 min), rapid RNA extraction (15 min), RT-LAMP reaction (40 min) and result reporting (< 2 min), were required for conduct the COVID-19 RT-LAMP-NBS diagnosis test, and the whole process could be completed approximately 60 min.




Figure 6. Primer design of COVID-19 RT-MCDA-BS assay

Up row, SARS-CoV-2 genome organization (GenBank: MN908947, Wuhan-Hu-1). The length of all genes was not displayed in scale. **Bottom row**, nucleotide sequence and location of F1ab and np gene used to design COVID-19 RT-LAMP primers. Part of nucleotide sequences of F1ab (Left) and N (Right) are listed. The sites of primer sequence were underline. Right arrows and Left arrows showed the sense and complementary sequence that are used.

* Note: Flab (Open reading frame la/b); S (Spike protein); E (Envelope protein); M (Membrane protein); N (Nucleoprotein); Accessory proteins (3, 6, 7a, 7b, and 9b).